Immune gene therapy in urology

被引：1

作者：

Kausch I. ^{[1
]}

Ardelt P. ^{[1
]}

Böhle A. ^{[1
]}

Ratliff T.L. ^{[1
]}

机构：

[1] Department of Urology, Medical University of Lübeck, Ratzeburger Allee 160, Lübeck

来源：

Current Urology Reports | 2002年 / 3卷 / 1期

关键词：

Gene Therapy; Potent Antitumor Immunity; Renal Cell Cancer; Tumor Cell Vaccination; Tumor Cell Vaccine;

D O I：

10.1007/s11934-002-0015-6

中图分类号：

学科分类号：

摘要：

Effective treatments are needed urgently for metastatic disease in bladder, prostate, and renal cell cancer. In the past few years, several new approaches for treating these conditions have been proposed, including gene therapy. A number of different strategies have been developed to accomplish urologic cancer gene therapy. Genetic immunomodulation strategies attempt to activate immune defense mechanisms against tumor cells by transfer of tumor antigens, cytokine genes, or strongly immunogenic cell surface molecules. In this review, we illustrate the recent developments in immune gene therapy. © 2002, Current Science Inc.

引用

页码：82 / 89

页数：7

共 42 条

[1]

Pettit S.J., Seymour K., O'Flaherty E., Kirby J.A., Immune selection in neoplasia: towards a microevolutionary model of cancer development, Br J Cancer, 82, pp. 1900-1906, (2000)

[2]

Radoja S., Frey A.B., Cancer-induced defective cytotoxic T lymphocyte effector function: another mechanism how antigenic tumors escape immune-mediated killing, Mol Med, 6, pp. 465-479, (2000)

[3]

Tzai T.S., Lin C.I., Shiau A.L., Wu C.L., Antisense oligonucleotide specific for transforming growth factor-beta 1 inhibit both in vitro and in vivo growth of MBT-2 murine bladder cancer, Anticancer Res, 18, pp. 1585-1590, (1998)

[4]

Gately M.K., Desai B.B., Wolitzky A.G., Et al., Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12, J Immunol, 147, pp. 874-882, (1991)

[5]

Gately M.K., Wolitzky A.G., Quinn P.M., Chizzonite R., Regulation of human cytolytic lymphocyte responses by interleukin-12, Cell Immunol, 143, pp. 127-142, (1992)

[6]

Mier J.W., Atkins M.B., Mechanisms of action and toxicity of immunotherapy with cytokines, Curr Opin Oncol, 5, pp. 1067-1072, (1993)

[7]

Gilboa E., How tumors escape immune destruction and what we can do about it, Cancer Immunol Immunother, 48, pp. 382-385, (1999)

[8]

Siemens D.R., Austin J.C., Hedican S.P., Et al., Viral vector delivery in solid-state vehicles: gene expression in a murine prostate cancer model, J Natl Cancer Inst, 92, pp. 403-412, (2000)

[9]

Bergelson J.M., Cunningham J.A., Droguett G., Et al., Isolation of a common receptor for Coxsackie B viruses and adenovirus 2 and 5, Science, 275, pp. 1320-1323, (1997)

[10]

Horiguchi Y., Larchian W.A., Kaplinsky R., Et al., Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model, Gene Therapy, 7, pp. 844-851, (2000)

← 1 2 3 4 5 →